What non‑pharmacological measures should be implemented in the management of patients with pulmonary tuberculosis?

Non-Pharmacological Management for TB Patients

Implement a multifaceted, patient-centered treatment strategy that combines enablers (transportation vouchers, convenient clinic hours, bilingual staff, reminder systems, social service assistance, outreach workers) with incentives (food assistance, housing support, stipends) to ensure treatment adherence and completion. 1

Core Non-Pharmacological Components

The 2016 ATS/CDC/ERS/IDSA guidelines provide the most comprehensive framework for non-pharmacological TB management, organized into two main categories:

Enablers (Interventions to Assist Treatment Completion)

• Transportation support: Provide vouchers or direct transportation assistance to ensure patients can attend appointments 1
• Accessible care delivery: Establish convenient clinic hours and locations that accommodate patient schedules 1
• Language-concordant care: Ensure clinic personnel speak the languages of populations served 1
• Systematic follow-up: Implement reminder systems and active follow-up for missed appointments 1
• Social service integration: Provide referrals for substance abuse treatment, counseling, housing assistance, and other social needs 1
• Outreach workers: Deploy bilingual/bicultural workers who can provide directly observed therapy (DOT), follow-up on missed appointments, monthly monitoring, transportation, sputum collection, and educational reinforcement 1
• Integrated care: Coordinate TB treatment with care for other conditions (HIV, diabetes, hepatitis) 1

Incentives (Interventions to Motivate Patients)

These should be tailored to individual patient needs and meaningful to each patient:

• Nutritional support: Food stamps, snacks, meals, restaurant and grocery store coupons 1
• Housing assistance: Help finding or direct provision of housing 1
• Material support: Clothing, personal products, books 1
• Financial incentives: Stipends 1
• Patient contracts: Formalized agreements outlining treatment expectations 1

Infection Control and Isolation Management

Criteria for De-isolation (When Patient Becomes Non-infectious)

For drug-susceptible TB, patients can be considered non-infectious when ALL of the following criteria are met 2:

1. Negligible likelihood of MDR-TB (no known exposure to MDR-TB, no history of poor compliance)
2. Received standard multidrug therapy for 2-3 weeks (or 5-7 days for smear-negative/rarely positive patients)
3. Demonstrated complete adherence to treatment (e.g., receiving DOT)
4. Clinical improvement evident (reduced cough frequency, decreased sputum AFB smear grade)
5. All close contacts identified, evaluated, and started on treatment if indicated (critical for children <4 years and immunocompromised contacts)

Important caveat: Hospitalized patients or those in congregate settings (shelters, correctional facilities) require three consecutive AFB-negative sputum smears collected 8-24 hours apart (with at least one early-morning specimen) before being considered non-infectious 2. This more stringent criterion applies because close contact identification and protection are not possible in these settings.

For MDR-TB patients: Apply the more stringent three consecutive negative sputum smear criteria 2.

Airborne Infection Isolation

• Maintain negative-pressure isolation until patients meet de-isolation criteria 2
• Early use of molecular techniques (GeneXpert MTB/RIF) is critical to rapidly identify drug resistance and guide appropriate isolation duration 3
• Infectiousness declines rapidly with effective treatment: to ~10% of baseline after 2 days of appropriate therapy, and <1% after 14-21 days 2

Clinical Monitoring and Follow-up

Monthly Assessments 1

1. Weight monitoring: Assess monthly to evaluate treatment response and adjust medication doses
2. Adherence assessment: Evaluate at every visit
3. Symptom monitoring: Track improvement in cough, fever, fatigue, night sweats
4. Adverse effect surveillance: Monitor for jaundice, dark urine, nausea, vomiting, abdominal pain, fever, rash, anorexia, malaise, neuropathy, arthralgias
5. Sputum collection: Monthly smears and cultures until two consecutive specimens are negative

Baseline and Periodic Testing 1

• HIV testing: All patients, with CD4 count and viral load if positive
• Hepatitis B/C screening: For patients with risk factors (injection drug use, birth in Asia/Africa, HIV infection)
• Diabetes screening: Fasting glucose or HbA1c for patients with risk factors (age >45 years, BMI >25 kg/m², first-degree relative with diabetes, high-risk ethnicity)
• Visual monitoring: For patients on ethambutol—baseline visual acuity and color discrimination tests, then monthly inquiries about visual disturbance

Management of Treatment Interruptions 1

During intensive phase:

• Lapse <14 days: Continue treatment to complete planned doses (within 3 months)
• Lapse ≥14 days: Restart treatment from the beginning

During continuation phase:

• Received ≥80% of doses: Continue therapy until all doses completed
• Received <80% of doses with lapse <3 months: Restart if cannot complete within recommended timeframe
• Received <80% of doses with lapse ≥3 months: Restart entire treatment (new intensive and continuation phases)

For patients lost to follow-up: Resend sputum for AFB smear, culture, and drug susceptibility testing upon return 1.

Patient Education and Counseling

Health education should be provided at treatment initiation 4, covering:

• Disease transmission and infection control measures
• Importance of adherence and consequences of treatment interruption
• Recognition and reporting of adverse effects
• Expected duration of treatment and monitoring requirements
• Contact tracing importance

Common Pitfalls to Avoid

1. Premature de-isolation: Do not discharge patients from isolation based solely on time on treatment without meeting all criteria, especially in congregate settings
2. Inadequate social support: Failure to address transportation, housing, and nutritional barriers leads to poor adherence
3. One-size-fits-all approach: Incentives and enablers must be individualized and culturally appropriate
4. Neglecting comorbidities: Failure to screen for and manage HIV, diabetes, hepatitis, and mental health conditions compromises outcomes
5. Insufficient follow-up systems: Passive approaches to missed appointments result in treatment interruptions and poor outcomes

The evidence strongly supports that non-pharmacological interventions are not optional add-ons but essential components of TB treatment that directly impact morbidity and mortality through improved adherence, reduced transmission, and better treatment outcomes 5, 6.